BioCryst Pharmaceuticals
BCRX
#4539
Rank
A$3.60 B
Marketcap
A$14.17
Share price
1.97%
Change (1 day)
3.92%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : A$1.46 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are A$1.46 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31A$0.94 B-39.14%
2024-12-31A$1.55 B8.84%
2023-12-31A$1.42 B15.01%
2022-12-31A$1.24 B29.44%
2021-12-31A$0.95 B108.28%
2020-12-31A$0.46 B135.21%
2019-12-31A$0.19 B41.26%
2018-12-31A$0.13 B14.47%
2017-12-31A$0.12 B-1.16%
2016-12-31A$0.12 B19.53%
2015-12-31A$0.10 B36.92%
2014-12-31A$74.82 M33.51%
2013-12-31A$56.04 M0.6%
2012-12-31A$55.7 M-15.25%
2011-12-31A$65.73 M51.95%
2010-12-31A$43.26 M-30.51%
2009-12-31A$62.25 M14.78%
2008-12-31A$54.23 M-39.06%
2007-12-31A$89 M48.23%
2006-12-31A$60.04 M7.66%
2005-12-31A$55.77 M1276.96%
2004-12-31A$4.05 M82.64%
2003-12-31A$2.21 M6.61%
2002-12-31A$2.08 M-53.49%
2001-12-31A$4.47 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Gilead Sciences
GILD
A$47.30 B 3,123.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$86.68 B 5,807.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
A$2.41 B 64.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.18 B-19.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$1.71 B 16.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
A$79.25 M-94.60%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
A$1.7 M-99.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
A$17.56 M-98.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$1.26 B-13.78%๐Ÿ‡บ๐Ÿ‡ธ USA